A novel peptide-based recognition probe for the sensitive detection of CD44 on breast cancer stem cells

Molecular and Cellular Probes

Volumn 29, Issue 6, 2015, Pages 492-499

  Cho, Jun Haeng ^a   Lee, Sang Choon ^a   Ha, Na Reum ^a   Lee, Su Jae ^a   Yoon, Moon Young ^a  

^a Hanyang University   (South Korea)

Author keywords

Breast cancer stem cell; CD44; PDPP; Peptide

Indexed keywords

HERMES ANTIGEN; POLYMER; POLYVALENT DIRECTED PEPTIDE POLYMER; UNCLASSIFIED DRUG; N-SUCCINIMIDYL 3-(2-PYRIDYLDITHIO)PROPIONATE; PEPTIDE; SUCCINIMIDE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIMIT OF DETECTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; 3T3 CELL LINE; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; COMBINATORIAL CHEMISTRY; EARLY CANCER DIAGNOSIS; FEMALE; FLOW CYTOMETRY; MCF-7 CELL LINE; METABOLISM; MOLECULAR DIAGNOSIS; MOUSE; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; FLOW CYTOMETRY; HUMANS; MCF-7 CELLS; MICE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASTIC STEM CELLS; NIH 3T3 CELLS; PEPTIDES; SENSITIVITY AND SPECIFICITY; SUCCINIMIDES;

EID: 84951573422     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2015.05.014     Document Type: Article

References (30)

1. Keysar S.B., Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 2010, 9:2450-2457.
2. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
3. American Cancer Society. Cancer facts & figures. Atlanta, GA: The Society. [p. v].
4. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics. CA: A Cancer J. Clin. 2011, 2011(61):409-418.
5. Nakshatri H. Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/PKH26+ cells to blame? breast cancer research. BCR 2010, 12:105.
6. Hsu T., Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc. Natl. Acad. Sci. U. S. A 2011, 108:15816-15821.
7. Hsiung P.L., Hardy J., Friedland S., Soetikno R., Du C.B., Wu A.P., et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat. Med. 2008, 14:454-458.
8. Seigneuric R., Gobbo J., Colas P., Garrido C. Targeting cancer with peptide aptamers. Oncotarget. 2011, 2:557-561.
9. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32:4943-4950.
10. Crompton K.E., Goud J.D., Bellamkonda R.V., Gengenbach T.R., Finkelstein D.I., Horne M.K., et al. Polylysine-functionalised thermoresponsive chitosan hydrogel for neural tissue engineering. Biomaterials 2007, 28:441-449.
11. Vance D., Shah M., Joshi A., Kane R.S. Polyvalency: a promising strategy for drug design. Biotechnol. Bioeng. 2008, 101:429-434.
12. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
13. Shipitsin M., Campbell L.L., Argani P., Werernowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
14. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69:4116-4124.
15. Hiraga T., Ito S., Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013, 73:4112-4122.
16. Park H.Y., Gedi V., Kim J., Park H.C., Han S.H., Yoon M.Y. Ultrasensitive diagnosis for an anthrax-protective antigen based on a polyvalent directed peptide polymer coupled to zinc oxide nanorods. Adv. Mater. 2011, 23:5425-5429.
17. Park H.Y., Lee K.J., Lee S.J., Yoon M.Y. Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol. Biotechnol. 2012, 51:212-220.
18. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
19. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367:1783-1791.
20. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer J. Clin. 2011, 61:69-90.
21. Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 2010, 362:513-520.
22. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
23. Baumann M., Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2010, 16:5091-5093.
24. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 2008, 5:474-486.
25. McDonald B., McAvoy E.F., Lam F., Gill V., de la Motte C., Savani R.C., et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J. Exp. Med. 2008, 205:915-927.
26. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429-1443.
27. Oh E.J., Park K., Kim K.S., Kim J., Yang J.A., Kong J.H., et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release: Official J. Control Release Soc. 2010, 141:2-12.
28. Charpentier M.S., Whipple R.A., Vitolo M.I., Boggs A.E., Slovic J., Thompson K.N., et al. Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. 2014, 74:1250-1260.
29. Karimi-Busheri F., Rasouli-Nia A., Mackey J.R., Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast cancer research. BCR 2010, 12:R31.
30. Mandal C.C., Ghosh-Choudhury N., Yoneda T., Choudhury G.G., Ghosh-Choudhury N. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol. Chem. 2011, 286:11314-11327.